JCC: 回肠和结肠组织中miRNA表达的差异性揭示了克罗恩氏病患者与健康受试者之间免疫调节分子特征的不同

2019-11-09 不详 MedSci原创

MicroRNA [miRNA]是克罗恩病[CD]中基因表达的关键的因子,它可能驱动CD组织间特异性分子改变的发生。在这项研究中,研究人员分析了CD与健康受试者的回肠和结肠组织中miRNA表达的差异,以期寻找出一些规律。

背景
MicroRNA [miRNA]是克罗恩病[CD]中基因表达的关键的因子,它可能驱动CD组织间特异性分子改变的发生。在这项研究中,研究人员分析了CD与健康受试者的回肠和结肠组织中miRNA表达的差异,以期寻找出一些规律。

方法
研究人员招募了一组CD患者和健康对照HC患者,并收集了临床数据。从末端回肠和乙状结肠的内窥镜活检标本中提取总RNA。使用NanoString Technologies定量测量miRNA表达水平。同时评估了每个miRNA的活检部位和诊断的统计显着性,并进行了多次测试校正。

结果
本项总共招募了23名CD和38名HC受试者;分析了112个样品,其中回肠51个,结肠61个。我们在健康组织中发现了47个部位差异表达的miRNA。九个miRNA在HC和CD中差异表达,其中miR-223-3p显示出年龄和性别之间的差异。而且miR-31-5p表达受疾病位置影响,可以作为CD中病变位置的生物标记。

结论
本项研究在健康人和CD患者的回肠和结肠组织中鉴定了差异表达的miRNA。同时某些miRNA表达与疾病位置有关。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1930741, encodeId=eeee1930e4116, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Oct 07 14:34:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771445, encodeId=79081e71445e1, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 24 21:34:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003485, encodeId=6403200348597, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Wed Jul 22 07:34:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793447, encodeId=cd8b1e9344755, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Wed Aug 19 11:34:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312371, encodeId=6fbe13123e192, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446102, encodeId=a161144610216, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511357, encodeId=b8e7151135e79, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2020-10-07 smallant2002
  2. [GetPortalCommentsPageByObjectIdResponse(id=1930741, encodeId=eeee1930e4116, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Oct 07 14:34:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771445, encodeId=79081e71445e1, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 24 21:34:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003485, encodeId=6403200348597, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Wed Jul 22 07:34:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793447, encodeId=cd8b1e9344755, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Wed Aug 19 11:34:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312371, encodeId=6fbe13123e192, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446102, encodeId=a161144610216, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511357, encodeId=b8e7151135e79, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1930741, encodeId=eeee1930e4116, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Oct 07 14:34:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771445, encodeId=79081e71445e1, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 24 21:34:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003485, encodeId=6403200348597, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Wed Jul 22 07:34:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793447, encodeId=cd8b1e9344755, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Wed Aug 19 11:34:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312371, encodeId=6fbe13123e192, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446102, encodeId=a161144610216, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511357, encodeId=b8e7151135e79, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1930741, encodeId=eeee1930e4116, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Oct 07 14:34:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771445, encodeId=79081e71445e1, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 24 21:34:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003485, encodeId=6403200348597, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Wed Jul 22 07:34:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793447, encodeId=cd8b1e9344755, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Wed Aug 19 11:34:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312371, encodeId=6fbe13123e192, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446102, encodeId=a161144610216, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511357, encodeId=b8e7151135e79, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1930741, encodeId=eeee1930e4116, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Oct 07 14:34:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771445, encodeId=79081e71445e1, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 24 21:34:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003485, encodeId=6403200348597, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Wed Jul 22 07:34:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793447, encodeId=cd8b1e9344755, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Wed Aug 19 11:34:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312371, encodeId=6fbe13123e192, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446102, encodeId=a161144610216, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511357, encodeId=b8e7151135e79, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-11-10 Homburg
  6. [GetPortalCommentsPageByObjectIdResponse(id=1930741, encodeId=eeee1930e4116, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Oct 07 14:34:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771445, encodeId=79081e71445e1, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 24 21:34:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003485, encodeId=6403200348597, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Wed Jul 22 07:34:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793447, encodeId=cd8b1e9344755, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Wed Aug 19 11:34:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312371, encodeId=6fbe13123e192, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446102, encodeId=a161144610216, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511357, encodeId=b8e7151135e79, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1930741, encodeId=eeee1930e4116, content=<a href='/topic/show?id=22f61180211' target=_blank style='color:#2F92EE;'>#miR#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11802, encryptionId=22f61180211, topicName=miR)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a27288, createdName=smallant2002, createdTime=Wed Oct 07 14:34:00 CST 2020, time=2020-10-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1771445, encodeId=79081e71445e1, content=<a href='/topic/show?id=655b31640c7' target=_blank style='color:#2F92EE;'>#分子特征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31640, encryptionId=655b31640c7, topicName=分子特征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=197038292186, createdName=zlawrance, createdTime=Mon Aug 24 21:34:00 CST 2020, time=2020-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2003485, encodeId=6403200348597, content=<a href='/topic/show?id=5b592889555' target=_blank style='color:#2F92EE;'>#克罗恩氏病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28895, encryptionId=5b592889555, topicName=克罗恩氏病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=139a316, createdName=wumeihua88, createdTime=Wed Jul 22 07:34:00 CST 2020, time=2020-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1793447, encodeId=cd8b1e9344755, content=<a href='/topic/show?id=d96c155e526' target=_blank style='color:#2F92EE;'>#RNA表达#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15575, encryptionId=d96c155e526, topicName=RNA表达)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=72bf2500198, createdName=小小小向日葵, createdTime=Wed Aug 19 11:34:00 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312371, encodeId=6fbe13123e192, content=<a href='/topic/show?id=e5571193321' target=_blank style='color:#2F92EE;'>#miRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11933, encryptionId=e5571193321, topicName=miRNA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1446102, encodeId=a161144610216, content=<a href='/topic/show?id=23f4380e5f9' target=_blank style='color:#2F92EE;'>#受试者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38075, encryptionId=23f4380e5f9, topicName=受试者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=24035191312, createdName=xinmeili, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511357, encodeId=b8e7151135e79, content=<a href='/topic/show?id=d47d40542cc' target=_blank style='color:#2F92EE;'>#回肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=40542, encryptionId=d47d40542cc, topicName=回肠)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sun Nov 10 15:34:00 CST 2019, time=2019-11-10, status=1, ipAttribution=)]
    2019-11-10 zhaojie88

相关资讯

JCC: 炎症性肠病患者出现恶性肿瘤的风险

本项研究旨在探讨炎症性肠病[IBD]患者中恶性肿瘤发生的趋势和预测因素。

JCC:青年人炎症性肠病患者心理疾病发病率和疾病感知的关联

患有炎症性肠病的年轻人[IBD]的心理疾病发病率明显增加。疾病认知可能是一个重要因素。这项研究旨在描述心理疾病发病率的普遍性和严重程度,并检查基线疾病认知与焦虑,抑郁和健康相关的生活质量[HRQoL]之间的关系。

JCC:新型遗传风险变异可以预测炎症性肠病患者的抗TNF药物反应效果

临床工作中一项重要的任务是鉴定哪种IBD患有对抗肿瘤坏死因子[TNF]治疗难以起到应答效果,以避免潜在的不良反应并采用不同的治疗策略。本项研究的目的是确定和验证临床和遗传因素,以预测IBD患者的抗TNF反应。

JCC: 低剂量甲氨蝶呤与抗TNF联合治疗炎症性肠病与使用大剂量甲氨蝶呤具有相似的疗效

甲氨蝶呤[MTX]是一种众所周知的免疫调节剂,可以用于治疗炎症性肠病[IBD],并且通常与生物制剂联合使用。但目前尚未确定用于联合治疗的理想MTX剂量。本研究旨在研究不同剂量的MTX在IBD中与抗TNF药物一起使用时对疗效和安全性结果的影响。

JCC: 粪便钙卫蛋白作为预测和监测炎症性肠病患者治疗后恶化后复发的有用工具

本项研究旨在评估治疗过程中前后粪便钙卫蛋白[Fcal]水平的变化与炎症性肠病患者的临床复发[IBD]之间的关系。

Gastric Cancer: CRP/前白蛋白是一种预测胃癌患者行根治性切除术后复发的新型炎症指标

血清白蛋白(PALB)可以预测胃癌(GC)患者的预后。但是,C反应蛋白和PALB(CRP / PALB)联合使用的预后价值仍不清楚。本项研旨在探究二者的关系。